Vitamin D and Lung Cancer; Association, Prevention, and Treatment

Wang, Weijie; Hu, Wentao; Xue, Shihang; Chen, Qi; Jiang, Yongsheng; Zhang, Haina; Zuo, Wei

doi:10.1080/01635581.2020.1844245

Cited by 17 publications

(17 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vitamin D is strongly related to survival and risk of NSCLC. There is therefore a presumption that alterations in the genes involved in the metabolic pathway of vitamin D may affect their expression and functionality [15,28,[36][37][38][39][40]. Each of the genes fulfills a unique and characteristic function within the metabolic process of vitamin D. We can therefore surmise that variations in one or more genes may entail a worse prognosis.…”

Section: Discussionmentioning

confidence: 99%

“…The genes that encode the enzymes involved in the vitamin D pathway are highly polymorphic [27]. These genetic alterations may influence the expression of those genes in lung tumor tissue, modifying the activity of vitamin D [15,28,36,[38][39][40][41]. Therefore, they may play a vital part in the development, progression, and prognosis of NSCLC [5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Genetic Polymorphisms on the Metabolic Pathway of Vitamin D and Survival in Non-Small Cell Lung Cancer

et al. 2021

View full text Add to dashboard Cite

Vitamin D has been associated with risk, development, and progression of cancer. However, the genes involved in its metabolism are highly polymorphic, compromising its activity. The aim of this study is to evaluate the association between the gene polymorphisms involved in the metabolic pathway of vitamin D and survival in patients with non-small-cell lung cancer (NSCLC). The study was designed as an observational cohort which included 194 Caucasians patients from southern Spain with NSCLC. Real-time polymerase chain reaction was used to analyze the following polymorphisms: CYP27B1 rs4646536, rs3782130, and rs10877012; CYP24A1 rs6068816 and rs4809957; GC rs7041; CYP2R1 rs10741657; VDR rs1544410 (BsmI), rs11568820 (Cdx-2), rs2228570 (FokI), rs7975232 (ApaI), and rs731236 (TaqI). Progression-free survival (PFS) and overall survival were assessed. Cox regression showed that rs4646536 was associated with PFS in the general population (p = 0.0233) and in the non-resected NSCLC subgroup (p = 0.0233). In the resected NSCLC subgroup, rs11568820 was associated with OS (p = 0.0129) and rs7041 with PFS (p = 0.0447). In the non-resected NSCLC subgroup, rs6068816 was associated with PFS (p = 0.0048) and OS (p = 0.0089) and rs731236 and rs7975232 were associated with OS (p = 0.0005) and PFS (p = 0.0002), respectively. The other polymorphisms showed no effect on the results. The rs4646536, rs6068816, rs7041, rs11568820, rs731236, and rs7975232 polymorphisms are associated with survival in NSCLC and may have a substantial role as prognostic markers of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Impact of Genetic Polymorphisms on the Metabolic Pathway of Vitamin D and Survival in Non-Small Cell Lung Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Therefore, the early treatment of adoptive immunotherapy after reducing the tumor load can benefit the patients to a greater extent. In addition, patients who received CIK more than seven times were significantly better than those with fewer treatments [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

The Combined Clinical Efficacy and Safety Analysis of Adoptive Immunotherapy with Radiotherapy and Chemotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis

Zhao¹,

He²,

Chen³

2022

Applied Bionics and Biomechanics

View full text Add to dashboard Cite

Objective. To explore the differential efficacy of chemoradiotherapy combined with adoptive immunotherapy and radiochemotherapy alone in patients with non-small-cell lung cancer (NSCLC). Methods. Qualified randomized controlled trial (randomized controlled trial, RCT), or nonrandomized concurrent controlled trial (NRCCT), published in various databases, including PubMed, EMBASE, Chinese journal full-text database, Medline, Cochrane database, and VIP Chinese database, and the Revman5. 0 software performed the data analysis. Results. We found the significantly different curative effect between the experimental and control groups ( OR = 1.94 , 95% CI (1.46, 2.58), P < 0.001 , I 2 = 0 % , Z = 4.59 ), effect of adoptive immunotherapy on the progression of disease ( OR = 1.80 , 95% CI (1.38, 2.35), P < 0.001 , I 2 = 0 % , Z = 4.33 ), adoptive immunotherapy on overall survival ( OR = 2.19 , 95% CI (1.60, 2.99), P < 0.001 , I 2 = 0 % , Z = 4.91 ), and adverse effects of adoptive immunotherapy ( OR = 1.76 , 95% CI (1.25, 2.48), P = 0.001 , I 2 = 0 % , Z = 3.26 ). Conclusion. Adoptive immunotherapy combined with microradiotherapy can decrease the recurrence of NSCLC and improve patient survival, as well as early patients can be benefited more significantly from immunotherapy.

show abstract

“…The role of vitamin D in some biological processes is well known, like the bone metabolism, or the calcium homeostasis and regulation [5]. However, its role in cancer is controversial, as serum vitamin D or vitamin D supplementation could play a key role in the prevention and treatment of many malignancies [6][7][8][9], although those promising findings were not confirmed in other studies [10,11]. Specifically, vitamin D deficiency has been extensively reported to be a negative prognostic factor in B-cell lymphomas (including DLBCL) [12][13][14][15], in which rituximab and lenalidomide are commonly used [16,17].…”

Section: Introductionmentioning

confidence: 99%

Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial

Jiménez‐Cortegana

Sánchez-Martínez

Palazón‐Carrión

et al. 2021

Cancers

View full text Add to dashboard Cite

The search of prognostic factors is a priority in diffuse large B-cell lymphoma (DLBCL) due to its aggressiveness. We have recently found that the level of circulating MDSCs is a good marker of survival in a translational study based on a trial (EudraCT Number: 2014-001620-29), using lenalidomide combined with R-GDP (rituximab plus gemcitabine, cisplatin, and dexamethasone). Since Vitamin D is a known immunomodulator, we have studied blood levels of these cell populations comparing patients with deficit of vitamin D levels (<15 ng/mL with those with normal levels >15 ng/mL. Mann–Whitney U test was used to compare cells distributions between groups, Wilcoxon test to compare cells distribution at different times and Spearman test to measure the association between cell populations. Patients with vitamin D deficit maintained the increased level of immune suppressor cells, whereas we observed a depletion of all immune suppressor cells in patients with normal vitamin D levels. In conclusion, we have confirmed the importance of vitamin D in the response to treatment in R/R DLBCL, suggesting that vitamin D deficit may be involved in the immune deficit of these patients, and thus, vitamin D supplementation in these patients may help to obtain a better response, warranting further investigation.

show abstract

Vitamin D and Lung Cancer; Association, Prevention, and Treatment

Cited by 17 publications

References 100 publications

Impact of Genetic Polymorphisms on the Metabolic Pathway of Vitamin D and Survival in Non-Small Cell Lung Cancer

Impact of Genetic Polymorphisms on the Metabolic Pathway of Vitamin D and Survival in Non-Small Cell Lung Cancer

The Combined Clinical Efficacy and Safety Analysis of Adoptive Immunotherapy with Radiotherapy and Chemotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis

Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial

Contact Info

Product

Resources

About